Phase I/II Study of Safety and Efficacy of Muscadine Plus (MPX) in Men With Prostate Cancer: a Randomized,Double-blind,Placebo Controlled Study of the Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

This research is being done to test an investigational product called Muscadine Plus in the treatment of men who have received initial therapy (surgery and or radiation, cryotherapy or brachytherapy) for prostate cancer and are experiencing a rise in their prostate-specific antigens (PSA) level.

开始日期2011-07-01

申办/合作机构

The Sidney Kimmel Comprehensive Cancer Center

[+2]

100 项与 Manpixiao Decoction 相关的临床结果

登录后查看更多信息

100 项与 Manpixiao Decoction 相关的转化医学

登录后查看更多信息

100 项与 Manpixiao Decoction 相关的专利（医药）

登录后查看更多信息

157

项与 Manpixiao Decoction 相关的文献（医药）

2024-12-31·Emerging Microbes & Infections

Evaluation of analytical performance of the STANDARD ^TM M10 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox virus

Article

作者: Gagliardi, Gloria ; Antinori, Spinello ; Mancon, Alessandro ; Rizzardini, Giuliano ; Salari, Federica ; Gori, Andrea ; Moschese, Davide ; Castagna, Antonella ; Bracchitta, Fiorenza ; Cutrera, Miriam ; Nozza, Silvia ; Giacomelli, Andrea ; Mileto, Davide ; Rizzo, Alberto ; Raccagni, Angelo Roberto ; Gismondo, Maria Rita

Monkeypox virus (MPXV) infection confirmation needs reliable polymerase chain reaction (PCR) assays; in addition, viral clade attribution is a key factor in containment measures, considering a more severe syndrome in clade I and the possibility of simultaneous circulation. This study evaluates the performance of all-in-one STANDARD M10 MPX/OPX (SD BIOSENSOR, South Korea - M10). Frozen samples from 205 subjects were selected and stratified according to routine test results (RealStar® Orthopoxvirus PCR Kit 1.0, Altona DIAGNOTICS, Germany - RS; RS-1): in detail, 100 negative skin lesions (SL) and 200 positive samples at the variable stage of infection were analysed. Positive samples were retested with RS (RS-2). Positive and Negative Percent Agreements (PPA, NPA) were calculated. The median (IQR) C_t values of RS and M10 (OPXV target) assays were highly similar. The PPA of M10 compared to RS-1 was 89.5% considering system interpretation, and 96.0% when the operator classified results as positive if any target was detected; NPA was 100%. Comparing the RS-2 run and M10, an overall concordance of 95.3% between assays was found; however, considering operator interpretation, M10 returned more positive results than RS-2. The occurrence of False-Negative results was likely associated with the influence of thawing on low viral concentration; no False-Positive tests were observed. All samples collected at the time of Mpox diagnosis were positive and M10 correctly attributed the clade (West-Africa/II). The M10 MPX/OPX assay demonstrated high reliability in confirming MPXV infection and clade attribution.

2024-04-01·Journal of Infection and Public Health

Monkeypox stigma and risk communication; Understanding the dilemma

Article

作者: Alaqeel, Meshal K ; Banjar, Weam M

Monkeypox (MPX) is a viral zoonotic disease that is endemic in Central and West African countries had affected countries in Asia, Europe, Africa, Australia, and South and North America. Some globally reported cases were linked to history of recent travel to endemic regions, however, official reports revealed homosexual practices among the majority of reported cases. In response to global increase MPX burden and number of cases, the WHO declared MPX a Public Health Emergency with International Concern (PHEIC) on July 23, 2022. The first MPX case in Saudi Arabia was a returning traveler from Europe to Riyadh on July 14, 2022. It is essential for policy makers to maintain neutral tone for health education messages and inform the public that MPX transmits via physical contact.

2024-04-01·Molecular Biotechnology

Proteome-Based Investigation Identified Potential Drug Repurposable Small Molecules Against Monkeypox Disease

Article

作者: Ahammad, Ishtiaque ; Keya, Chaman Ara ; Bhattacharjee, Arittra ; Chowdhury, Zeshan Mahmud ; Salimullah, Md ; Das, Keshob Chandra

Monkeypox Virus (MPXV), the causative agent of Monkeypox (MPX) disease, is an emerging zoonotic pathogen spreading in different endemic and non-endemic nations and creating outbreaks. MPX treatment mainly includes Cidofovir and Tecovirimat but they have several side effects and solely depending on these drugs may promote the emergence of drug-resistant variants. Hence, new drugs are required to control the spread of the disease. In this study, we explored the MPXV proteome to suggest repurposable drugs. DrugBank screening revealed drugs such as Brinzolamide, Dorzolamide, Methazolamide, Zidovudine, Gemcitabine, Hydroxyurea, Fludarabine, and Tecovirimat as controls. Structural analogs of these compounds were extracted from ChEMBL Database. After Molecular docking and Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET)-based screening, we identified Zidovudine (binding affinity-5.9 kcal/mol) and a Harmala alkaloid (2S,4R)-4-(9H-Pyrido[3,4-b]indol-1-yl)-1,2,4-butanetriol (binding affinity - 6.6 kcal/mol) against L2R receptor (Thymidine Kinase). Moreover, Fludarabine (binding affinity - 6.4 kcal/mol) and 5'-Dehydroadenosine (binding affinity - 6.4 kcal/mol) can strongly interact with the I4L receptor (Ribonucleotide reductase large subunit R1). Molecular Dynamics (MD) simulations suggest all of these compounds can change the C-alpha backbone, residue mobility, compactness, and solvent accessible surface area of L2R and I4L. Our results strongly suggest that these drug repurposing small molecules are worth exploring in vivo and in vitro for clinical applications.

项与 Manpixiao Decoction 相关的新闻（医药）

2024-05-08

·PRNewswire

Pixelgen Technologies Announces Peer-Review Publication on Molecular Pixelation Technology in Nature Methods

Researchers demonstrate first sequencing-based, optics-free method for spatial proteomics of single cells STOCKHOLM, May 8, 2024 /PRNewswire/ -- Pixelgen Technologies, a leader in spatial proteomics for single cells, announced today that researchers from Pixelgen, the Karolinska Institute, Imperial College of London, and the Royal Institute of Technology in Sweden have demonstrated a ground-breaking sequencing-based method for identifying the relative locations of highly-multiplexed immunologically relevant proteins in single cells, in a peer-reviewed article published in Nature Methods. The Molecular Pixelation (MPX) technology used in the study is the first to demonstrate spatial proteomics of single cells without light, enabling multiplexing, throughput, and spatial resolution in 3D for proteomics-level single cell research. The study, titled "Molecular Pixelation: Spatial Proteomics of single cells by sequencing," illustrates the ability of a DNA-barcode-based strategy to identify and visualize in 3D the spatial protein organization of immune cell receptors. How immune cell surface receptors are organized relative to each other, and their behavior control many of a cell's vital functions. Researchers have traditionally studied spatial surface protein organization with microscopy, using fluorophore-labeled antibodies on immobilized samples or with flow cytometry. These approaches have limitations in multiplexing and sample throughput, and data is visualized only in two dimensions. MPX uses DNA-tagged antibodies (Antibody-Oligonucleotide Conjugates, AOCs) bound to their protein targets on chemically fixed cells to survey cell surface protein arrangement in a highly multiplexed fashion. Sample immobilization or single cell compartmentalization is not required and assays are performed in standard reaction tubes. DNA pixels, which are unique nano-sized DNA spheres, are used to form associations between neighboring AOCs, allowing the spatial analysis of protein arrangement. The generated amplicons are then sequenced, and reads are computationally arranged into spatial proteomics networks of each single cell. The study processed a heterogeneous 80-plex protein panel targeting T cells, NK cells, B cells, dendritic cells and monocytes. It demonstrated the ability of MPX to generate single-cell-based data on protein abundance from peripheral blood mononuclear cells (PBMC). It also identified known and novel patterns of protein spatial organization in chemokine-stimulated T-cells. The results show the ability of MPX to define cell states based on spatial arrangement of surface proteins. "This study highlights the importance of spatial proteomics of single cells, which could bring new insights into cell motility and activation, drug mode-of-action, and drug-target discovery based on spatial clustering and cell-to-cell communication," said Filip Karlsson, Pixelgen Chief Technology Officer, and lead author on the paper. "We believe MPX has significant advantages over traditional technologies and will play an important role in guiding the development of therapies that aim to spatially reorganize cell surface proteins to support immune-modulatory activities, including pre-tuning immune synapses in CAR-T cells in cancer, and more broadly pave the way for a new generation of medicines and diagnostics." "Being able to analyze the spatial distribution and colocalization of proteins in individual white blood cells as demonstrated in this study has tremendous value for our research into how cells are regulated by cell-cell interactions and adapt their function in response to environmental factors," added Petter Brodin, MD, PhD, Professor of pediatric immunology at Karolinska Institute and Imperial College London, and co-author of the paper. "This additional spatial dimension offers an orthogonal layer of information to the protein and mRNA abundance measurements we are used to studying and we are keen to learn what it will tell us in the future." About Pixelgen Technologies Pixelgen Technologies AB was founded in 2020 by a team of passionate, experienced innovators and entrepreneurs with a vision to bring a new spatial understanding to biology by mapping cell surface proteins and their spatial inter-relationships. The company has developed Molecular Pixelation, a DNA-based visualization technology for analyzing cell surface proteins, to gain novel insights into cellular activity that will advance better medicines and diagnostics. Pixelgen is headquartered in Stockholm, Sweden. Contacts Corporate: Annika Branting [email protected] +46 762-69 68 46 Media: Susan Thomas [email protected] +1 (619) 540-9195 SOURCE Pixelgen Technologies

寡核苷酸

2023-02-09

·PRNewswire

Europe to Spend USD 18 Million in Monkeypox Testing by the End of 2023 - Arizton

More than 25,300 confirmed Monkeypox cases in Europe (November 2022), the Demand for Monkeypox Testing Tremendously Increasing CHICAGO, Feb. 9, 2023 /PRNewswire/ -- According to Arizton's latest research report, the Europe monkeypox testing market to spend USD 18 million by the end of 2023. Growing development of rapid testing methods, advancements in PCR technology, and increasing collaborations among the vendors are the growing trends in the market. Continue Reading Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025 There are only a few MPX test kits available in the market. However, governments make efforts to control the virus due to its rapid spread across the region. As case numbers and surveillance measures increase, the MPX testing market is anticipated to grow substantially in the coming months. The Monkeypox outbreak gives companies huge opportunities to develop new diagnostics to detect MPXV. In September 2022, Cosmos Health, a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, over-the-counter (OTC) medications, and medical devices, announced that it entered a contract with Virax Biolabs, a UK-based diagnostics company, focused on the prevention and detection of viral diseases wherein, Virax Biolabs became the distributor of MPXV real-time PCR detection kits. Cosmos Health has exclusive distribution rights for Cyprus and Greece, with the opportunity to distribute test kits across Europe. Europe Monkeypox Testing Market Report Scope Click Here to Download the Free Sample Report Increasing Development by Several vendors is driving the Europe monkeypox testing market growth In July 2022, ELITechGroup, a France-based privately held manufacturer and distributor of IVD equipment, strategically partnered with Jiangsu Bioperfectus Technologies for monkeypox virus testing across Europe. In June 2022, Eurobio Scientific launched a CE-marked monkeypox screening test available for hospital use in France. On 8th June 2022, altona Diagnostics, a medical diagnostic company headquartered in Germany, announced the launch of the RealStar Zoonotic Orthopoxvirus PCR Kit 1.0, a real-time RT-PCR based reagent system for the detection of zoonotic (non-variola) Orthopoxvirus species-specific DNA – including MPVX DNA of the Central and West African strains. On 27th June 2022, Cepheid collaborated with the UK-based global molecular diagnostics company BioGX and announced a partnership between the two companies to provide a PCR test for MPX that will run on the GeneXpert system. In July 2022, the altona Diagnostics company launched another monkeypox virus detection kit, Flexstar Monkeypox virus PCR Detection Mix 1.5, for research purposes. Bioactiva Diagnostica is another Germany-based company that offers PCR kits for monkeypox virus detection. Europe Monkeypox Testing Market Insights Syndromic tests for monkeypox detection are expected to witness strong growth because they can distinguish monkeypox from other harmful diseases, allowing for easier treatment. On 25th May 2022, Roche and its subsidiary TIB Molbiol announced that they had developed a unique LightMix Modular Virus kit that simultaneously detects orthopoxvirus and offers information on whether an MPXV is present or not, including all MPXV from both the West African and Central African forms of the virus. Rapid tests in the Europe monkeypox testing market are also expected to witness strong growth due to their rapid results and increasing consumer preference. Demand for MPXV testing kits is expected to decline during the forecast as the cases can be seen declining due to increased surveillance, contact tracing, and increasing vaccination across Europe. Key Company Profiles Hoffmann-La Roche Qiagen altona Diagnostics Autobio Applied DNA Sciences Aurora Biomed bioactiva diagnostica Beijing Hotgen Biotech BioGX CERTEST BIOTEC Creative Biogene CorDx CLONIT Eurobio Scientific FireGene GenScript Guangzhou Pluslife Biotech JOYSBIO (Tianjin) Biotechnology Nanjing Synthgene Medical Technology RayBiotech Life Sansure Biotech Virax Biolabs Wondfo Shanghai Biogerm Medical Technology Market Segmentation Type PCR Lateral Flow Assay Others End-User Laboratories Hospitals & Clinics Others Region Europe EU-5 Spain France UK Germany Italy Central, Eastern, and Southern Europe Netherlands Portugal Switzerland Nordic Sweden Denmark Check Out Some of the Top-Selling Research Related Reports: In Vitro Diagnostics Market - The global in vitro diagnostics market size crossed USD 105.23 billion in 2022 and is expected to reach USD 127.56 billion by 2028. HIV Rapid Test Kits Market - The global HIV rapid test kits market size was valued at USD 1.437 billion in 2022 and is expected to reach USD 1.68 billion by 2028. COVID-19 Rapid Antigen Test Kits Market - The global COVID-19 rapid antigen tests market was valued at USD 4 billion in 2021 and is expected to reach USD 743.07 million by 2027. Hematology Diagnostics Market - The hematology diagnostics market size was valued at USD 3 billion in 2021 and is expected to reach USD 4 billion by 2027. Table of Content 1 RESEARCH METHODOLOGY 2 RESEARCH OBJECTIVES 3 RESEARCH PROCESS 4 SCOPE & COVERAGE 4.1 MARKET DEFINITION 4.1.1 INCLUSIONS 4.1.2 EXCLUSIONS 4.1.3 MARKET ESTIMATION CAVEATS 4.2 BASE YEAR 4.3 SCOPE OF THE STUDY 4.3.1 MARKET SEGMENTATION BY TYPE 4.3.2 MARKET SEGMENTATION BY END-USER 4.3.3 MARKET SEGMENTATION BY GEOGRAPHY 5 REPORT ASSUMPTIONS & CAVEATS 5.1 KEY CAVEATS 5.2 CURRENCY CONVERSION 5.3 MARKET DERIVATION 6 PREMIUM INSIGHTS 6.1 OVERVIEW 7 MARKET AT A GLANCE 8 INTRODUCTION 8.1 OVERVIEW 9 MARKET OPPORTUNITIES & TRENDS 9.1 DEVELOPMENT OF RAPID TESTING METHODS 9.2 ADVANCES IN PCR TECHNOLOGY 9.3 VENDOR COLLABORATIONS 10 MARKET GROWTH ENABLERS 10.1 INCREASED GOVERNMENT SURVEILLANCE 10.2 EASE OF REGULATIONS FOR PRODUCT APPROVALS 10.3 INCREASED PRODUCT LAUNCHES 11 MARKET RESTRAINTS 11.1 DECLINE IN MPX CASES 11.2 MPX VACCINE APPROVAL & ACCESS 11.3 FALSE MPX TEST RESULTS 12 MARKET LANDSCAPE 12.1 MARKET OVERVIEW 12.1.1 INSIGHTS BY TYPE 12.1.2 INSIGHTS BY END-USER 12.1.3 INSIGHTS BY GEOGRAPHY 12.2 FIVE FORCES ANALYSIS 12.2.1 THREAT OF NEW ENTRANTS 12.2.2 BARGAINING POWER OF SUPPLIERS 12.2.3 BARGAINING POWER OF BUYERS 12.2.4 THREAT OF SUBSTITUTES 12.2.5 COMPETITIVE RIVALRY 13 TEST TYPE 13.1 MARKET SNAPSHOT & GROWTH ENGINE 13.2 MARKET OVERVIEW 13.3 PCR 13.3.1 MARKET OVERVIEW 13.3.2 MARKET SIZE & FORECAST 13.4 LATERAL FLOW ASSAYS 13.4.1 MARKET OVERVIEW 13.4.2 MARKET SIZE & FORECAST 13.5 OTHERS 13.5.1 MARKET OVERVIEW 13.5.2 MARKET SIZE & FORECAST 14 END-USER 14.1 MARKET SNAPSHOT & GROWTH ENGINE 14.2 MARKET OVERVIEW 14.3 LABORATORIES 14.3.1 MARKET OVERVIEW 14.3.2 MARKET SIZE & FORECAST 14.4 HOSPITALS & CLINICS 14.4.1 MARKET OVERVIEW 14.4.2 MARKET SIZE & FORECAST 14.5 OTHERS 14.5.1 MARKET OVERVIEW 14.5.2 MARKET SIZE & FORECAST 15 GEOGRAPHY 15.1 MARKET SNAPSHOT & GROWTH ENGINE 15.2 MARKET OVERVIEW 16 EU-5 16.1 MARKET OVERVIEW 16.2 MARKET SIZE & FORECAST 16.3 KEY COUNTRIES 16.3.1 SPAIN: MARKET SIZE & FORECAST 16.3.2 FRANCE: MARKET SIZE & FORECAST 16.3.3 UK: MARKET SIZE & FORECAST 16.3.4 GERMANY: MARKET SIZE & FORECAST 16.3.5 ITALY: MARKET SIZE & FORECAST 17 CENTRAL, EASTERN & SOUTHERN EUROPE 17.1 MARKET OVERVIEW 17.2 MARKET SIZE & FORECAST 17.3 KEY COUNTRIES 17.3.1 NETHERLANDS: MARKET SIZE & FORECAST 17.3.2 PORTUGAL: MARKET SIZE & FORECAST 17.3.3 SWITZERLAND: MARKET SIZE & FORECAST 18 NORDICS 18.1 MARKET OVERVIEW 18.2 MARKET SIZE & FORECAST 18.3 KEY COUNTRIES 18.3.1 SWEDEN: MARKET SIZE & FORECAST 18.3.2 DENMARK: MARKET SIZE & FORECAST 19 COMPETITIVE LANDSCAPE 19.1 COMPETITION OVERVIEW 19.2 MARKET SHARE ANALYSIS 19.2.1 F. HOFFMANN-LA ROCHE 19.2.2 QIAGEN 20 KEY COMPANY PROFILES 20.1 F. HOFFMANN-LA ROCHE 20.1.1 BUSINESS OVERVIEW 20.1.2 PRODUCT OFFERINGS 20.1.3 KEY STRATEGIES 20.1.4 KEY STRENGTHS 20.1.5 KEY OPPORTUNITIES 20.2 QIAGEN 21 OTHER PROMINENT VENDORS 21.1 ALTONA DIAGNOSTICS 21.1.1 BUSINESS OVERVIEW 21.1.2 PRODUCT OFFERINGS 21.2 AUTOBIO 21.3 APPLIED DNA SCIENCES 21.4 AURORA BIOMED 21.5 BIOACTIVA DIAGNOSTICA 21.6 BEIJING HOTGEN BIOTECH 21.7 BIOGX 21.8 CERTEST BIOTEC 21.9 CREATIVE BIOGENE 21.10 CORDX 21.11 CLONIT 21.12 EUROBIO SCIENTIFIC 21.13 FIREGENE 21.14 GENSCRIPT 21.15 GUANGZHOU PLUSLIFE BIOTECH 21.16 JOYSBIO (TIANJIN) BIOTECHNOLOGY 21.17 NANJING SYNTHGENE MEDICAL TECHNOLOGY 21.18 RAYBIOTECH LIFE 21.19 SANSURE BIOTECH 21.20 VIRAX BIOLABS 21.21 WONDFO 21.22 SHANGHAI BIOGERM MEDICAL TECHNOLOGY 22 REPORT SUMMARY 22.1 KEY TAKEAWAYS 22.2 STRATEGIC RECOMMENDATIONS 23 QUANTITATIVE SUMMARY 23.1 MARKET BY GEOGRAPHY 23.2 MARKET BY TYPE 23.3 MARKET BY END-USER 24 APPENDIX 24.1 ABBREVIATIONS About Us :   Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services. We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.  Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.  Click Here to Contact Us  Call: +1-312-235-2040            +1 302 469 0707  Mail: [email protected] Photo: Logo: SOURCE Arizton Advisory & Intelligence

100 项与 Manpixiao Decoction 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
萎缩性胃炎	临床1期	中国	北京中医药大学	2021-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01317199 (ASCO_GU2017)	临床2期	非转移性前列腺癌	125	4000 mg of MPX	齋鹹範鏇築襯憲淵範構(鑰鬱鹹築觸鏇廠膚蓋選) = 網鑰艱膚網積廠範顧窪顧齋願壓齋鑰淵簾願夢 (遞艱積壓範繭廠構觸淵 )	-	2017-03-29
NCT01317199 (CTgov)	临床1/2期	前列腺癌	143	Placebo oral capsule (Phase 2: Placebo Control)	衊鏇簾遞構積觸願顧選(夢窪獵齋網餘觸製鏇繭) = 壓觸夢夢壓憲顧積簾蓋網憲鑰鑰齋鬱醖蓋夢醖 (觸網廠廠廠廠鑰憲蓋構, 選衊餘繭顧壓膚窪餘繭 ~ 襯鬱繭鏇膚鬱顧廠構顧) 更多	-	2018-07-18
NCT01317199 (CTgov)	临床1/2期	前列腺癌	143	Low-dose MPX (Phase 2: Low-dose MPX)	衊鏇簾遞構積觸願顧選(夢窪獵齋網餘觸製鏇繭) = 願簾鹽淵選鏇製構遞繭網憲鑰鑰齋鬱醖蓋夢醖 (觸網廠廠廠廠鑰憲蓋構, 窪蓋廠鹽膚願廠鏇鬱鑰 ~ 齋夢繭範願蓋鏇夢廠鹹) 更多	-	2018-07-18